abiraterone acetate, Janssen Biotech, MAGNITUDE, mCRPC, ນິຣະພາຣິບ
Niraparib ແລະ abiraterone acetate plus prednisone ຖືກອະນຸມັດໂດຍ FDA ສໍາລັບ BRCA-mutated metastatic castration-resistant prostate cancer
August 2023: The fixed dose combination of niraparib and abiraterone acetate (Akeega, Janssen Biotech, Inc.), along with prednisone, has been approved by the Food and Drug Administration for adult patients with castration-resista..
Bayer HealthCare Pharmaceuticals Inc, Darolutamide, docetaxel, ນູເບກາ
ເມັດ Darolutamide ໄດ້ຮັບການອະນຸມັດໂດຍ FDA ສໍາລັບມະເຮັງ prostate ທີ່ລະອຽດອ່ອນຮໍໂມນ metastatic
August 2022: Darolutamide (Nubeqa, Bayer HealthCare Pharmaceuticals Inc.) tablets combined with docetaxel were approved by the Food and Drug Administration for adult patients with metastatic hormone-sensitive prostate cancer (mHS..
gallium Ga 68 gozetotide, Locametz, lutetium Lu 177 vipivotide tetraxetan, mCRPC, Novartis, ພລູວິກໂຕ, PSMA
Pluvicto ໄດ້ຮັບການອະນຸມັດໂດຍ FDA ສໍາລັບມະເຮັງ prostate castration-ທົນທານຕໍ່ metastatic
April 2022: The Food and Drug Administration approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan, Advanced Accelerator Applications USA, Inc., a Novartis company) for the treatment of adult patients with prostate-specific mem..
doppler, ED, dysfunction erectile, HIFU, HIFU beam, Ultrasound ສຸມໃສ່ຄວາມເຂັ້ມສູງສຸດ, prostate cells
Ultrasound ສຸມໃສ່ຄວາມເຂັ້ມສູງສຸດ
March 2022: HIFU (High Intensity Focused Ultrasound) is a cutting-edge therapy that uses focused, high-energy ultrasound waves to heat and kill cancerous parts of the prostate gland. The target tissue is heated to 880 to 980 degre..
GnRH, HERO, ວິທະຍາສາດ Myovant, ຮໍໂມນປ່ອຍ gonadotropin ທາງປາກ, ORGOVYX, receptor antagonist, relugolix
FDA ໄດ້ອະນຸມັດ relugolix ສໍາລັບການປິ່ນປົວມະເຮັງ prostate ຂັ້ນສູງ
ເດືອນສິງຫາ 2021: ຕົວຕ້ານທານຕົວຮັບຮໍໂມນທີ່ປ່ອຍຕົວ gonadotropin (GnRH) ຄັ້ງທໍາອິດ, relugolix (ORGOVYX, Myovant Sciences, Inc. ), ໄດ້ຮັບການອະນຸມັດຈາກອົງການອາຫານແລະຢາໃນວັນທີ 18 ທັນວາ 2020, ສໍາລັບຄົນເຈັບຜູ້ໃຫຍ່ທີ່ພົບ.